AFJK Stock — Aimei Health Technology Co., Ltd Ordinary Share

Aimei Health Technology Co., Ltd Ordinary Share (AFJK)

Updated October 2, 2026.

AFJK is a Stock. Total return is 19.3% over the past 2.7 years, 45.1 points behind SPY at 64.4%.

Aimei Health Technology Co., Ltd is a blank-check company incorporated in 2023 that currently has no significant operations and seeks to complete a merger or business combination with one or more companies, potentially in the biopharmaceutical, medical technology, diagnostics, or related healthcare sectors. The company does not currently distribute to shareholders. This structure appeals to investors interested in participating in a yet-to-be-announced acquisition in the healthcare industry, though blank-check companies carry risks including dilution and the possibility that no suitable business combination occurs.

AFJK performance versus SPY

Price and return data through 2026-10-02.

Total return is 19.3% over the past 2.7 years, 45.1 points behind SPY at 64.4%. Over the past year its total return — price change plus distributions reinvested — is 6.8%. Its deepest 1-year drawdown was 86.8%.

AFJK key facts

Asset type

Stock

Asset class

Equity

Inception date

01/22/2024

Distribution frequency

None

Last close

$12.11 (as of 2026-10-02)

Market cap

$38,344,281

Average volume

600.0

Beta

0.852

Payout ratio

0.0%

P/E ratio

173.0

Forward P/E

0.0

EPS

$0.07

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) is the latest regular payout annualized by the fund's stated frequency, divided by the last close. Issuers often publish this as “Distribution Rate” on the fact sheet. Trailing-12-month yield is the sum of distributions paid in the last 12 months, split-adjusted, divided by the last close. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AFJK risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 86.8%.

Who may consider AFJK — and who may not

It is a weaker fit for investors who need monthly cash flow (AFJK does not currently distribute); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

Frequently asked questions